Atea Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Good afternoon. I'm JP Sommadossi, Chairman and CEO of Atea Pharmaceuticals. And I would like to thank Jefferies for the opportunity to present today. This slideshow has the standard forward-looking statements, and as you know, further information can be found in our most recent regulatory filing.
Since the founding of the company, our vision has not changed, with a focus on the discovery and development of antiviral drug for the treatment, cure, and prophylaxis of serious viral disease where there is significant unmet medical need or where we can make a huge difference.
For our COVID program, patient enrollment is underway in the global Phase 3 SUNRISE-3 trial. Our upcoming milestones include an interim analysis expected end of the year in Q4, top-line results in the first half of 2024, and NDA submission which is targeted for the end of 2024.
We are also advancing our second-generation protease inhibitor program, which we believe will have a very unique profile, and I'm really looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
